News

Show
news from

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Syncona leads CHF 35 million Series A financing in Anaveon, a new Immuno-oncology company

Search